Research News

Pharma Courses 
PAGE Admission

  • The COVID-19 pandemic is throwing up unique challenges for health systems. It presents particular challenges for patients who receive regular haemodialysis. These patients with damaged kidneys, also known as uremic patients, are particularly vulnerable to infection and may exhibit greater variations in clinical symptoms and infectivity. 

  • Scientists from France conducted a small clinical trials and reported that hydroxychloroquine, an antimalarial medicine, treatment is significantly associated with viral load reduction or disappearance in COVID-19 patients and they also reported that azithromycin along with hydroxychloroquine can faster the recovery.

  • In the early days of a COVID‐19 infection outbreak, pediatric patients were rather rare, who were thought to be not susceptible to it. However, along with the emerging of familial aggregation, children suffered from COVID‐19 infection were gradually appeared. It is reported by researchers that Clinical and CT (computed tomography) features in pediatric patients with COVID‐19 infection are different than adults. The study was conducted by Dr. Jianbo Shao, MD, Department of Imaging Center, Wuhan Children's Hospital and team. And it is published in Pediatric Pulmonology on 5th March, 2020.

  • Transfusion of red blood cells (RBCs) is a life-saving treatment for numerous conditions such as severe anaemia, injury-related trauma, supportive care in cardiovascular surgery, transplant surgery, pregnancy-related complications, solid malignancies and blood-related cancers.

  • A new therapy for tongue cancer could be in the offing, with a team of scientists at the Department of Biotechnology’s Hyderabad-based Centre for DNA Fingerprinting and Diagnostics coming out with a new insight into the mechanism by which an anti-cancer protein helps in the development of cancer when it mutates.

  • A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks.

  • Researchers at the University of Texas Southwestern Medical Center and University of Chicago have discovered that bacteria that usually live in the gut can accumulate in tumors and improve the effectiveness of immunotherapy in mice. The study, which will be published March 6 in the Journal of Experimental Medicine (JEM), suggests that treating cancer patients with Bifidobacteria might boost their response to CD47 immunotherapy, a wide-ranging anti-cancer treatment that is currently being evaluated in several clinical trials.

  • How individuals respond to government advice on preventing the spread of COVID-19 will be at least as important, if not more important, than government action, according to a new commentary from researchers at the University of Oxford and Imperial College London in the UK, and Utrecht University and the National Institute for Public Health and the Environment in the Netherlands.

Subscribe to Research News